J&J's RYBREVANT FASPRO Combo Delivers 77% Response Rate In Head And Neck Cancer
Johnson & Johnson (JNJ) reported Phase 1b/2 study results showing that RYBREVANT FASPRO combined with pembrolizumab and carboplatin achieved a 77% response rate in patients with recurrent or metastatic head and neck cancer. The trial involved 22 patients, with 14% experiencing complete responses. JNJ's stock closed at $263.81 on October 23, 2026, and was up 1.00% in pre-market trading.
How this was made
The 30-second read
Why it matters
If OrigAMI-5 confirms benefit, J&J could strengthen its head and neck oncology franchise and improve odds for later-line label expansion; if not, the stock may retrace pipeline optimism.
Market read
Traders get a concrete efficacy datapoint (77% confirmed ORR in a defined subgroup) plus a regulatory-process milestone (Priority Review) that can shift pipeline probability for J&J’s oncology assets.
What to watch
The article provides limited detail on subgroup durability beyond median follow-up and does not quantify comparative arms, which can matter for later-line and label expansion expectations.
Background
RYBREVANT FASPRO is subcutaneous amivantamab plus hyaluronidase, being studied beyond EGFR-mutated non-small cell lung cancer.
Ticker impact
J&J reported OrigAMI-4 Cohort 5 Phase 1b/2 results for RYBREVANT FASPRO plus pembrolizumab and carboplatin in first-line head and neck cancer.
Likely upward bias as traders price improved probability of later-line and Phase 3 success, tempered by early-stage limitations and safety consistency.
The article discloses specific response-rate and durability metrics plus an FDA Priority Review application, which are actionable pipeline catalysts, but the data are Phase 1b/2 and not a regulatory decision.
Market effects
Reinforces investor appetite for EGFR/MET bispecific oncology strategies and subcutaneous antibody formulations in combination regimens.
Primarily US large-cap pharma sentiment, with spillover to oncology-focused biotech peers.
ESMO-disclosed data can influence global clinical expectations and competitive positioning in head and neck squamous cell carcinoma.
Counterpoint
High response rates in a small Phase 1b/2 cohort may not translate to Phase 3 endpoints, so the market could overreact ahead of OrigAMI-5.
Key entities
- companyJohnson & Johnson
Reported Phase 1b/2 OrigAMI-4 Cohort 5 results and noted an FDA Priority Review application for later-line head and neck cancer.
- drugRYBREVANT FASPRO
Subcutaneous amivantamab and hyaluronidase-lpuj combination evaluated with pembrolizumab and carboplatin.
- clinical_studyOrigAMI-4 (Cohort 5)
Phase 1b/2 study assessing subcutaneous amivantamab plus hyaluronidase with PD-1 inhibitor and chemotherapy in first-line HNSCC.
- clinical_studyOrigAMI-5
Ongoing pivotal Phase 3 study supporting continued evaluation of the combination.
- regulatorU.S. Food and Drug Administration
Granted Priority Review status for a later-line head and neck cancer application for RYBREVANT FASPRO.
